[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Oruka Therapeutics, Inc. Common Stock (ORKA)
Oruka Therapeutics (ORKA) stock is trending upwards after the FDA cleared its IND application for a Phase 2a trial of ORKA-001 in Psoriasis. The stock is seeing increased engagement and mentions across social media platforms.
About Oruka Therapeutics, Inc. Common Stock
Oruka Therapeutics, Inc. Common Stock (ORKA) is a healthcare stock.
Oruka Therapeutics, Inc. Common Stock uses the ticker $ORKA for trading. Listed in the Stocks and category.
Insights #
- Oruka Therapeutics, Inc. Common Stock (ORKA) trading volume is up XXXXXX% from the previous month.
- Oruka Therapeutics, Inc. Common Stock (ORKA) social dominance is up XXXXX% from the previous week.
- Oruka Therapeutics, Inc. Common Stock (ORKA) engagements is up XXXXXX% from the previous month.
- Oruka Therapeutics, Inc. Common Stock (ORKA) mentions is up XXXXXXXX% from the previous month.
- Oruka Therapeutics, Inc. Common Stock (ORKA) posts created is up XX% from the previous week.
Price: $XXXXX #
Price 24-Hour Chart Data
ORKA is trending upwards due to positive sentiment, analyst ratings, and insider activity, coupled with rising trading volume and market capitalization, supported by mentions in recent social media posts. The current price is $14.80, with a 24-hour increase of 3.65%.
| 24-Hour | 7-Day | 30-Day |
|---|---|---|
| XXXX% | -XXXX% | XXXXX% |
1-Year High: $XXXXX on 2024-10-21
1-Year Low: $XXXX on 2025-04-08
AltRank: XXXXX #
AltRank 24-Hour Chart Data
Oruka Therapeutics, Inc. Common Stock (ORKA) is currently AltRank #1,438 based on combined combined social and market metrics
Daily Average: XXXXX
1 Week: XXXXX -XXX
1 Month: XXXXX +1,424
6 Months: XXXXX +664
1 Year: XXXXX +308
1-Year High: XXXXX on 2025-07-20
1-Year Low: XX on 2024-09-15
Galaxy Score: XXXXX #
Galaxy Score 24-Hour Chart Data
Current Value: XXXXX
Daily Average: XX
1 Week: XX -X
1 Month: XX +5
6 Months: XX +23
1 Year: XX +28
1-Year High: XX on 2025-03-03
1-Year Low: XX on 2025-04-04
Engagements: XXX #
Engagements 24-Hour Chart Data
Current Value: XXX
Daily Average: XXXXX
1 Week: XXXXXX +713%
1 Month: XXXXXX +736%
6 Months: XXXXXXX -XX%
1 Year: XXXXXXX +4,586%
1-Year High: XXXXXX on 2024-12-02
1-Year Low: X on 2025-05-13
| Social Network | X |
|---|---|
| Engagements | XXX |
Mentions: XX #
Mentions 24-Hour Chart Data
Current Value: XX
Daily Average: XX
1 Week: XX +20%
1 Month: XXX +3,771%
6 Months: XXX +112%
1 Year: XXXXX +12,844%
1-Year High: XXX on 2025-06-28
1-Year Low: X on 2024-08-20
| Social Network | X |
|---|---|
| Mentions | XX |
Creators: XX #
Creators 24-Hour Chart Data
XX unique social accounts have posts mentioning Oruka Therapeutics, Inc. Common Stock (ORKA) in the last XX hours which is down XX% from XX in the previous XX hours
Daily Average: XX
1 Week: XX -XXXX%
1 Month: XXX +6,867%
6 Months: XXX +369%
1 Year: XXX +9,950%
1-Year High: XXX on 2025-06-28
1-Year Low: X on 2024-08-20
The most influential creators that mention Oruka Therapeutics, Inc. Common Stock in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @Quantumup1 | X | XXXXX | X | XXX |
Sentiment: XXX% #
Sentiment 24-Hour Chart Data
Current Value: XXX%
Daily Average: XX%
1 Week: XX% -XX%
1 Month: XXX% no change
6 Months: XXX% +25%
1 Year: XXX% +50%
1-Year High: XXX% on 2024-08-23
1-Year Low: XX% on 2025-01-16
Most Supportive Themes
- Positive Sentiment: (80%) Positive sentiment is fueled by positive analyst ratings, insider activity, and increased social media engagement.
Most Critical Themes
- Alternative Treatment: (19.37%) Concerns arise as alternative treatments offer similar treatments.
Network engagement breakdown:
| Network | Positive | % | Neutral | % | Negative | % |
|---|---|---|---|---|---|---|
| X | XX | X% | XXX | XX% | X | X% |
| Total | XX | X% | XXX | XX% | X | X% |
Social Dominance: XXXXXXX% #
Social Dominance 24-Hour Chart Data
Current Value: XXXXXXX%
Daily Average: XXXXXXX%
1 Week: XXXXXXX% +0.00031999999999999997%
1 Month: XXXXXX% +0.00010000000000000026%
6 Months: XXXXXX% -XXXXXX%
1 Year: XXXXXX% +0.0039%
1-Year High: XXXXX% on 2025-06-28
1-Year Low: XXXXXX% on 2024-08-23
Market Dominance: XXXXXXXXXXXXXXXXXXXXX% #
Market Dominance 24-Hour Chart Data
Current Value: XXXXXXXXXXXXXXXXXXXXX%
Daily Average: X%
1-Year High: XXXXX% on 2024-09-11
1-Year Low: XXXXXXX% on 2025-03-14
Market Cap: $XXXXXXXXXXX #
Market Cap 24-Hour Chart Data
Current Value: $XXXXXXXXXXX
Daily Average: $XXXXXXXXXXX
1 Week: $XXXXXXXXXXX -$10%
1 Month: $XXXXXXXXXXX +$21%
6 Months: $XXXXXXXXXXX +$25%
1-Year High: $XXXXXXXXXXXXX on 2024-10-21
1-Year Low: $XXXXXXXXXXX on 2025-04-08
Top assets mentioned In the posts about Oruka Therapeutics, Inc. Common Stock in the last XX hours
Sarepta Therapeutics, Inc. (SRPT) Johnson & Johnson (JNJ) Tesla, Inc. (TSLA) Wing Finance (WING) Telcoin (TEL) Pinterest, Inc. (PINS) Litecoin (LTC) SuperRare (RARE) Electronic Arts Inc. (EA)
Top topics mentioned In the posts about Oruka Therapeutics, Inc. Common Stock in the last XX hours
$383800ks, sqns, qqq, spx, dltr, $srpt, pltr, amzn, vz, dal, djt, meta, msft, mbx, $ucbjy, $jnj, $orkas, nvda, telo, $tsla, celc, spy, $glue, $cnl, iwm, amc, prism, vfs, qubt, abus, $csan, mcb, $comm, $dsy, $hnrg, $odvwz, $gree, $floc, $ferau, curated, ema, $uncy, $wing, $1810hk, xiaomi, googl, $opof, $ccec, $bnrg, $hlx, $clps, hc, xpof, mira, gass, xch, lyft, dtc, $ppbt, $hdsn, $myps, veru, $strr, $mntsw, $tcx, $ldp, $em, $srg, $tel, kyrgyzstani som, soc, srm, op, apm, ltc, $plow, $podc, $pins, $ltc, $gcbc, $pvbc, cabo, goog, alts, akro, mrna, amgn, $rare, rklb, $ctm, $eton, $rgs, $agfy, cash flow, stocks, ind, $ea, $lbgj, $hal, $benf
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"H.C. Wainwright reit'd $ORKA Buy/$45 after Oruka📰that the FDA had cleared its IND application for its Phase 2a trial of ORKA-001 (the company's long-acting anti-IL-23p19 antibody) in moderate-to-severe PsO called EVERLAST-A. $ABBV $PTGX - $JNJ #EDAV25 H.C. Wainwright said in its note: "This program is a randomized double-blind placebo-controlled Phase 2a trial designed to evaluate the safety and efficacy of a single dose level of ORKA-001 in moderate-to-severe psoriasis patients. EVERLAST-A will enroll approximately XX patients randomized 3:1 to receive ORKA-001 or matching placebo. The"
@Quantumup1 on X 2025-07-23 18:20:33 UTC 3528 followers, 1201 engagements
"Oruka Therapeutics $ORKA cleared to launch its Phase 2a EVERLAST-A trial for ORKA-001 in psoriasis. The study could support once-a-year dosing and long-term remission. Early data to be presented at EADV in September"
@PrismMarketView on X 2025-07-21 21:59:57 UTC 4678 followers, XXX engagements
"$ORKA $SPX $GOOGL $NVDA $XIAOMI $XK $MSFT $AAPL $TSLA $VWAGY $CAR $HTZ $AMZN $ABNB $DJT $DAL $MP $REMX $THC $INTC $AMD $CRWD $IONQ $BA $CAVA $AMRK $DLTR $EQIX $SHOP $NSC $TD $TSM $TROW $HUM $GL $SQNS $LX $AUTL $CNL $GLUE $FFAI $PET $SRPT $GLD $CL $ZC $ZN $ZT $DX 🌐"
@AponiaAnalytics on X 2025-07-21 15:55:26 UTC 5002 followers, XXX engagements
"$ORKA $SQNS $LX $AUTL $CNL $GLUE $FFAI $VZ $CLF $DPZ $DLTR $TSLA $PET $SRPT 🌐"
@AponiaAnalytics on X 2025-07-21 15:54:41 UTC 4989 followers, XX engagements